09.00, Wednesday 24 January 2018
The Academy convened a scoping roundtable to examine recent developments in the use of real world evidence.
This roundtable brought together senior representatives from across academia, industry, the NHS, regulatory agencies and funders to examine the environment for the use of real world evidence (RWE) in research and development of new therapies. This roundtable forms part of the follow-up work to our 2015 workshop on real world evidence, which focused on regulatory acceptability of RWE, and examined how the landscape has changed since then.
The roundtable was co-chaired by Sir Alasdair Breckenridge CBE FRSE FMedSci, Former Chair of the Medicines and Healthcare products Regulatory Agency, and Professor Andrew Morris FMedSci, Director of Health Data Research UK, and took place on 24 January 2018 at the Academy’s offices at 41 Portland Place, London, W1B 1QH. The summary meeting report has now been published and can be found on the right hand side of this page.
This meeting was invitation only. For further details please contact email@example.com.